Pinetree Therapeutics, Inc
PineTree Therapeutics Inc. is a preclinical stage biotechnology company dedicated to developing disruptive therapies in oncology and other diseases. The company focuses on innovative platforms such as AbReptor and Taer-Tab, which involve bi-specific and multi-specific antibody technologies aimed at degrading membrane-bound and extracellular proteins, and targeting difficult-to-target receptors on cancer cells. With a team of accomplished scientific and business leaders, PineTree Therapeutics is committed to advancing targeted biologic therapeutics for unmet medical needs, collaborating with major pharmaceutical companies like AstraZeneca, and supporting cutting-edge research in immuno-oncology and immunology. The company is based in Cambridge, MA, and emphasizes a collaborative, innovative, and inclusive work environment.
Industries
Nr. of Employees
small (1-50)
Pinetree Therapeutics, Inc
West Cambridge Scientific Park, 767C Concord Ave, Cambridge MA 02138
Patents
Neuropilin-1 specific binding peptide, fusion protein fused with same, and use thereof
US-10400022-B2
View DetailsTumor tissue-penetrating peptide specific to neuropilin and fusion protein having same peptide fused therein
US-9975933-B2
View Details
Neuropilin-1 specific binding peptide, fusion protein fused with same, and use thereof
US-10400022-B2
View DetailsTumor tissue-penetrating peptide specific to neuropilin and fusion protein having same peptide fused therein
US-9975933-B2
View DetailsProducts
Multispecific antibody platform for targeted protein degradation
A modular multispecific antibody development platform engineered to engage targets and promote degradation of membrane-bound and extracellular proteins for therapeutic intervention.
Bispecific antibody platform targeting challenging cancer receptors
Bispecific antibody platform engineered to engage unique and difficult-to-target receptors expressed on cancer cells across multiple tumor types to enable targeted therapeutic approaches.
Multispecific antibody platform for targeted protein degradation
A modular multispecific antibody development platform engineered to engage targets and promote degradation of membrane-bound and extracellular proteins for therapeutic intervention.
Bispecific antibody platform targeting challenging cancer receptors
Bispecific antibody platform engineered to engage unique and difficult-to-target receptors expressed on cancer cells across multiple tumor types to enable targeted therapeutic approaches.
Services
Option and licensing agreements and strategic partnerships to advance preclinical therapeutic candidates into external clinical development and commercialization.
Collaborative projects that apply machine learning and large-dataset analysis to support biotherapeutic discovery and biomarker identification.
Option and licensing agreements and strategic partnerships to advance preclinical therapeutic candidates into external clinical development and commercialization.
Collaborative projects that apply machine learning and large-dataset analysis to support biotherapeutic discovery and biomarker identification.
Expertise Areas
- Targeted protein degradation
- Bispecific and multispecific antibody engineering
- Preclinical oncology development
- Antibody discovery and protein engineering
Key Technologies
- Multispecific/bispecific antibody engineering
- Antibody-mediated targeted protein degradation
- ELISA and Meso Scale Discovery immunoassays
- Multi-color flow cytometry
News & Updates
Pinetree has entered into an agreement with AstraZeneca for a preclinical EGFR degrader candidate, with potential deal value over $500 million including milestone payments.
The grant supports research for PineTree's next-generation biotherapeutics development for solid tumors, and the company raised $23.5 million in Series A1 funding.
The company received funding to accelerate its research in large datasets, machine learning, and AI for drug discovery.
Pinetree has entered into an agreement with AstraZeneca for a preclinical EGFR degrader candidate, with potential deal value over $500 million including milestone payments.
The grant supports research for PineTree's next-generation biotherapeutics development for solid tumors, and the company raised $23.5 million in Series A1 funding.
The company received funding to accelerate its research in large datasets, machine learning, and AI for drug discovery.